Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Month, Open-Label, Flexible-Dosage (100 to 250 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil (CEP-10953) in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder (With an Open-Ended Extension Period)

NCT00228553 is registered in ClinicalTrials.gov with Cephalon as lead sponsor.

NCT NCT00228553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00228553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Month, Open-Label, Flexible-Dosage (100 to 250 mg/Day) Extension Study of the Safety and Efficacy of Armodafinil (CEP-10953) in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder (With an Open-Ended Extension Period)
Lead sponsor
Cephalon
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2004
Completion date
July 31, 2006
Enrollment
743 (actual)
Sites
100

Conditions

As the registry lists them; a condition with its own page is linked.

chronic shift work sleep disorder, excessive daytime sleepiness, narcolepsy, obstructive sleep apnea/hypopnea syndrome